别名 Catabolin、IL-1 beta、IL-1B + [6] |
简介 Potent pro-inflammatory cytokine (PubMed:10653850, PubMed:12794819, PubMed:28331908, PubMed:3920526). Initially discovered as the major endogenous pyrogen, induces prostaglandin synthesis, neutrophil influx and activation, T-cell activation and cytokine production, B-cell activation and antibody production, and fibroblast proliferation and collagen production (PubMed:3920526). Promotes Th17 differentiation of T-cells. Synergizes with IL12/interleukin-12 to induce IFNG synthesis from T-helper 1 (Th1) cells (PubMed:10653850). Plays a role in angiogenesis by inducing VEGF production synergistically with TNF and IL6 (PubMed:12794819). Involved in transduction of inflammation downstream of pyroptosis: its mature form is specifically released in the extracellular milieu by passing through the gasdermin-D (GSDMD) pore (PubMed:33377178, PubMed:33883744). Acts as a sensor of S.pyogenes infection in skin: cleaved and activated by pyogenes SpeB protease, leading to an inflammatory response that prevents bacterial growth during invasive skin infection (PubMed:28331908). |
作用机制 IL-1β抑制剂 [+1] |
原研机构 |
在研适应症 |
非在研适应症 |
最高研发阶段批准上市 |
首次获批国家/地区 韩国 |
首次获批日期2012-03-13 |
靶点 |
作用机制 IL-1β抑制剂 |
最高研发阶段批准上市 |
首次获批国家/地区 美国 |
首次获批日期2009-06-17 |
作用机制 IL-1α抑制剂 [+1] |
在研机构 |
在研适应症 |
最高研发阶段批准上市 |
首次获批国家/地区 美国 |
首次获批日期2008-02-27 |
开始日期2025-12-01 |
申办/合作机构 |
开始日期2025-06-15 |
申办/合作机构 |
开始日期2025-04-30 |